As weight loss medications continue to grow in popularity, there’s a buzz building around one treatment in particular — Orforglipron. Unlike injectable weight loss medications such as Wegovy or Mounjaro, Orforglipron is taken as a once-daily tablet, offering a needle-free alternative that could change the game for many patients.

But the big question remains: when will Orforglipron be available in the UK?

Let’s explore what we know so far, from trial progress to expected launch dates — and what you can do in the meantime if you’re interested in this breakthrough medication.

Table of Contents

Current Status: Where Is Orforglipron Now?

Orforglipron is currently in Phase 3 clinical trials. These are large-scale studies involving thousands of participants across multiple countries, designed to evaluate:

Effectiveness
Long-term safety
Side effect profile
Comparisons to existing weight loss treatments

The results of these trials will be crucial in determining whether Orforglipron is approved by global regulators, including:

MHRA (Medicines and Healthcare products Regulatory Agency) in the UK
EMA (European Medicines Agency) in Europe
FDA (Food and Drug Administration) in the United States

Expected UK Launch Date

According to pharmaceutical company Eli Lilly, Orforglipron is expected to be submitted for regulatory approval in late 2025.

If all goes well, the anticipated timeline for UK availability looks like this:

Late 2025 – Regulatory submission to MHRA and EMA
Early 2026 – Conditional launch in private clinics and pharmacies
Mid to Late 2026 – Potential rollout via the NHS (if approved for public use)

Please note that timelines can change depending on regulatory processes, clinical outcomes, and global demand.

How Will It Be Prescribed in the UK?

At launch, Orforglipron is expected to be available:

Privately, through registered clinics such as MedCare Health Clinic
Via online consultations, with prescription delivery across the UK
Possibly on the NHS, though this will depend on NICE guidelines and cost-effectiveness assessments

In the meantime, many patients are already expressing interest in the oral GLP-1 option as a more accessible and manageable weight loss treatment.

Why This Launch Is Highly Anticipated

Orforglipron offers several advantages that are generating excitement:

Oral tablet format – no injections required
Strong early trial results – up to 14.7% weight loss in studies
Easier to store and transport than injectable medications
May be more cost-effective and scalable compared to current options

These features could make it more appealing — and more widely adopted — once released.

What to Do While You Wait

If you’re considering Orforglipron, you can start preparing now:

Book a weight loss consultation at MedCare Health Clinic
Discuss your eligibility for GLP-1 medications currently available (e.g., Wegovy, Mounjaro, Saxenda)
Get baseline health checks like BMI, blood glucose levels, and lifestyle assessment
Follow updates on our blog for the latest Orforglipron news

We’re here to help you explore all your options and build a personalised plan, whether you’re looking to start now or wait until Orforglipron becomes available.

Final Thoughts

Orforglipron is one of the most highly anticipated treatments in the pipeline for weight loss and type 2 diabetes. With early 2026 set as the likely launch window, there’s a lot to look forward to — especially for those who prefer pills over injections.

Stay connected with MedCare Health Clinic for the latest updates, professional advice, and access to private weight loss treatments as soon as they become available.